Patrick Harrison Carroll Sells 15,000 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 15,000 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $22.07, for a total transaction of $331,050.00. Following the transaction, the insider now directly owns 196,941 shares in the company, valued at $4,346,487.87. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hims & Hers Health Stock Down 0.9 %

Hims & Hers Health stock opened at $23.41 on Friday. The company has a market capitalization of $5.03 billion, a P/E ratio of 53.21 and a beta of 1.06. The firm has a 50 day moving average price of $18.75 and a 200-day moving average price of $18.45. Hims & Hers Health, Inc. has a twelve month low of $6.58 and a twelve month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the business posted ($0.04) earnings per share. Equities analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Nisa Investment Advisors LLC grew its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC increased its holdings in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the period. CWM LLC lifted its stake in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares in the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at $111,000. Finally, Amalgamated Bank increased its holdings in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the period. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of several recent research reports. TD Cowen increased their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday. Bank of America raised their price target on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Piper Sandler reissued a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Truist Financial lifted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Canaccord Genuity Group upped their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $21.21.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.